These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22505276)

  • 1. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.
    Zein CO; Lopez R; Fu X; Kirwan JP; Yerian LM; McCullough AJ; Hazen SL; Feldstein AE
    Hepatology; 2012 Oct; 56(4):1291-9. PubMed ID: 22505276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feldstein AE; Lopez R; Tamimi TA; Yerian L; Chung YM; Berk M; Zhang R; McIntyre TM; Hazen SL
    J Lipid Res; 2010 Oct; 51(10):3046-54. PubMed ID: 20631297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
    Zein CO; Yerian LM; Gogate P; Lopez R; Kirwan JP; Feldstein AE; McCullough AJ
    Hepatology; 2011 Nov; 54(5):1610-9. PubMed ID: 21748765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.
    Van Wagner LB; Koppe SW; Brunt EM; Gottstein J; Gardikiotes K; Green RM; Rinella ME
    Ann Hepatol; 2011; 10(3):277-86. PubMed ID: 21677329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
    Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
    Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet.
    Yalniz M; Bahçecioğlu IH; Kuzu N; Celebi S; Ataseven H; Ustündağ B; Ozercan IH; Sahin K
    Dig Dis Sci; 2007 Sep; 52(9):2380-6. PubMed ID: 17415655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis.
    Vial P; Riquelme A; Pizarro M; Solís N; Madariaga JA; Aguayo G; Duarte I; Soza A; Accatino L; Arrese M
    Ann Hepatol; 2006; 5(1):25-9. PubMed ID: 16531961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
    Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
    Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
    Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates.
    Waddington EI; Croft KD; Sienuarine K; Latham B; Puddey IB
    Atherosclerosis; 2003 Mar; 167(1):111-20. PubMed ID: 12618275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
    Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
    J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.
    Wu J; Zhao MY; Zheng H; Zhang H; Jiang Y
    Acta Pharmacol Sin; 2010 Oct; 31(10):1367-75. PubMed ID: 20835270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.
    Alkhouri N; Berk M; Yerian L; Lopez R; Chung YM; Zhang R; McIntyre TM; Feldstein AE; Hazen SL
    Dig Dis Sci; 2014 Jul; 59(7):1617-24. PubMed ID: 24464211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) -- preliminary findings.
    Oliveira CP; Faintuch J; Rascovski A; Furuya CK; Bastos Mdo S; Matsuda M; Della Nina BI; Yahnosi K; Abdala DS; Vezozzo DC; Alves VA; Zilberstein B; Garrido AB; Halpern A; Carrilho FJ; Gama-Rodrigues JJ
    Obes Surg; 2005 Apr; 15(4):502-5. PubMed ID: 15946429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
    Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
    J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.